Prospective, multi-center, phase II clinical trial. The study plans to enroll 146 patients
with multiple lung cancers. After signing the informed consent, they were screened to meet
the admission and discharge criteria, and received microwave ablation treatment.
Electromagnetic navigation bronchoscope-guided intrapulmonary microwave ablation or
percutaneous microwave ablation was selected according to the patient's wishes and the
evaluation of the surgeon. After the operation, they were randomized and the experimental
group accepted PD-1 immune checkpoint inhibitor treatment (microwave ablation combined with
Camrelizumab treatment does not exceed 16 cycles, or disease progression/worsening or
confirmed imaging disease progression, or withdrawal for any reason), the control group does
not After receiving any treatment, the two groups were followed up closely (36 months after
the last treatment, including safety follow-up and survival follow-up).
Multiple Primary Lung Cancer
Microwave ablation plus Camrelizumab
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.